William M Pardridge

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 23

Top Venues

Molecular pharmaceutics

Pharmaceutics

Pharmaceutical research

Pharmaceuticals (Basel, Switzerland)

The Lipogene Company, Inc.

UCLA Life Sciences (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The Lipogene Company, Inc. May 01 2016 - Jun 30 2020

United States

Founder and Chief Scientific Officer

ArmaGen, Inc. Jul 01 2003 - Mar 01 2020

United States

Founder and Chief Scientific Officer :: Blood-brain barrier drug delivery

Ronald Reagan UCLA Medical Center Jul 01 1978 - Jun 30 2013

United States

Distinguished Professor Emeritus :: Medicine

Ronald Reagan UCLA Medical Center Jul 01 1976 - Jun 30 1978

United States

Fellow in Endocrinology & Metabolism :: Medicine

Boston University Medical Campus Jul 01 1974 - Jun 30 1976

United States

Intern/Resident :: Internal Medicine

Education History

UCLA Life Sciences Sep 01 1965 - Jun 30 1969

United States

BSC :: Chemistry

Publications

William M Pardridge
Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs. Pharmaceutical research 40 (3) (2023)
William M Pardridge
Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs. Pharmaceutical research (2023)
William M Pardridge
Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs. Pharmaceutical research 40 (3) (2023)
William M Pardridge
Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs. Pharmaceutical research 40 (3) (2023)
William M Pardridge
Advanced Blood-Brain Barrier Drug Delivery. Pharmaceutics 15 (1) (2022)
William M Pardridge
A Historical Review of Brain Drug Delivery. Pharmaceutics 14 (6) (2022)
William M Pardridge
Advanced Blood-Brain Barrier Drug Delivery. Pharmaceutics 15 (1) (2022)
William M Pardridge
Advanced Blood-Brain Barrier Drug Delivery. Pharmaceutics 15 (1) (2022)
William M Pardridge
Kinetics of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor. Pharmaceuticals (Basel, Switzerland) 15 (1) (2021)
William M Pardridge, Tom Chou
Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor. Pharmaceuticals (Basel, Switzerland) 14 (6) (2021)
Joshua Yang, Jiahong Sun, Demi M Castellanos, William M Pardridge, Rachita K Sumbria
Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice. Molecular pharmaceutics 17 (8) (2020)
Hungyen Lee, Dahai Jiang, William M Pardridge
Lyoprotectant Optimization for the Freeze-Drying of Receptor-Targeted Trojan Horse Liposomes for Plasmid DNA Delivery. Molecular pharmaceutics 17 (6) (2020)
William M Pardridge
Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery. Pharmaceuticals (Basel, Switzerland) 13 (11) (2020)
Jiahong Sun, Ruben J Boado, William M Pardridge, Rachita K Sumbria
Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice. Molecular pharmaceutics 16 (8) (2019)
Rudy Chang, Abrar Al Maghribi, Victoria Vanderpoel, Vitaly Vasilevko, David H Cribbs, Ruben Boado, William M Pardridge, Rachita K Sumbria
A Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. Molecular pharmaceutics 17 (1) (2019)
Roberto Giugliani, Luciana Giugliani, Fabiano de Oliveira Poswar, Karina Carvalho Donis, Amauri Dalla Corte, Mathias Schmidt, Ruben J Boado, Igor Nestrasil, Carol Nguyen, Steven Chen, William M Pardridge
Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial. Orphanet journal of rare diseases 13 (1) (2018)
William M Pardridge, Ruben J Boado, Roberto Giugliani, Mathias Schmidt
Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 32 (2) (2018)
William M Pardridge
Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 31 (6) (2018)
Rudy Chang, Abrar Al Maghribi, Victoria Vanderpoel, Vitaly Vasilevko, David H Cribbs, Ruben Boado, William M Pardridge, Rachita K Sumbria
Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. Molecular pharmaceutics 15 (11) (2018)
William M Pardridge, Ruben J Boado, Daniel J Patrick, Eric Ka-Wai Hui, Jeff Zhiqiang Lu
Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor. Molecular pharmaceutics 15 (11) (2018)
Rudy Chang, Jillian Knox, Jae Chang, Aram Derbedrossian, Vitaly Vasilevko, David Cribbs, Ruben J Boado, William M Pardridge, Rachita K Sumbria
Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease. Molecular pharmaceutics 14 (7) (2017)
Ruben J Boado, William M Pardridge
Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. Molecular pharmaceutics 14 (4) (2017)
Ruben J Boado, Jeff Zhiqiang Lu, Eric Ka-Wai Hui, William M Pardridge
Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. Molecular pharmaceutics 15 (2) (2017)

William M Pardridge.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

William M Pardridge